Chromosomal translocations in cancer and their relevance for therapy

Purpose of review Recurring chromosomal abnormalities are considered the primary genetic change in oncogenesis as well as an important indicator for tumor phenotype and clinical outcome. This review highlights recent findings regarding the genes associated with chromosomal translocations. Recent findings A great number of novel fusion genes associated with chromosomal translocations have been cloned. These novel fusion genes are found in the smaller part of various malignancies, and it can be expected that the significance of novel fusion gene occurrence for oncogenesis will be clarified in the not too distant future. Observation of high frequencies of mutations in NOTCH1, NPM and JAK2 in T-cell acute lymphoblastic leukemia, acute myeloid leukemia with normal karyotype and myeloproliferative disorders (polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis) have provided important suggestions for a better understanding of chromosomal translocations. This is because all these genes had already been identified as genes associated with chromosomal translocations in a small subset of specific phenotypes of hematologic malignancies. Summary This review summarizes recent findings associated with chromosomal translocations including newly identified fusion genes, a novel mechanism of fusion gene formation and their relevance for novel targeted therapies. Continuing attempts to identify genes associated with chromosomal translocations can be expected to provide further insights into the significance of various gene alterations in cancer and the development of novel targeted therapies.

[1]  S. Bohlander,et al.  A BCR–JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia , 2005, Genes, chromosomes & cancer.

[2]  S. Armstrong,et al.  Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. , 2005, Blood.

[3]  W. Hiddemann,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Global approach to the diagnosis of leukemia using gene expression profiling , 2022 .

[4]  Shinobu Saito,et al.  The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22 , 2005, Oncogene.

[5]  H. Mitsuya,et al.  Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22) , 2005, Leukemia.

[6]  K. Mitani,et al.  Cloning and characterization of the novel chimeric gene TEL/PTPRR in acute myelogenous leukemia with inv(12)(p13q13). , 2005, Cancer research.

[7]  Peter Marynen,et al.  Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). , 2005, Blood.

[8]  Y. Ishikawa,et al.  EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12) , 2005, Genes, chromosomes & cancer.

[9]  Jen-Fen Fu,et al.  MLL is fused to EB1 (MAPRE1), which encodes a microtubule‐associated protein, in a patient with acute lymphoblastic leukemia , 2005, Genes, chromosomes & cancer.

[10]  C. Schoch,et al.  The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1 , 2005, Leukemia.

[11]  B Johansson,et al.  Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations , 2005, Leukemia.

[12]  W. Hiddemann,et al.  AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes , 2005, Genes, chromosomes & cancer.

[13]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[14]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[15]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[16]  H. F. Barker,et al.  The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. , 2005, Cancer research.

[17]  Hideaki Nakajima,et al.  Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. , 2005, The Journal of clinical investigation.

[18]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[19]  Shigeru Chiba,et al.  Identification of a SRC‐like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation , 2005, Genes, chromosomes & cancer.

[20]  F. Lo‐Coco,et al.  8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes , 2005, Genes, chromosomes & cancer.

[21]  R. Siebert,et al.  Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL , 2005, Leukemia.

[22]  Guoqiang Chen,et al.  AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[24]  Dario Campana,et al.  FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. , 2005, Blood.

[25]  R. Pieters,et al.  Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Slovak,et al.  AML1-FOG2 fusion protein in myelodysplasia. , 2004, Blood.

[27]  Lucia Altucci,et al.  Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway , 2005, Nature Medicine.

[28]  D. Gilliland,et al.  KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32) , 2005, Leukemia.

[29]  C. Gervais,et al.  A new translocation t(9;11)(q34;p15) fuses NUP98 to a novel homeobox partner gene, PRRX2, in a therapy-related acute myeloid leukemia , 2005, Leukemia.

[30]  H. F. Barker,et al.  Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM 1 to JAK 2 , 2005 .

[31]  S. Armstrong,et al.  Targeting FLT 3 in primary MLL-gene – rearranged infant acute lymphoblastic leukemia , 2005 .

[32]  Peter Marynen,et al.  Fusion of EML 1 to ABL 1 in T-cell acute lymphoblastic leukemia with cryptic t ( 9 ; 14 ) ( q 34 ; q 32 ) , 2005 .

[33]  E. Devilard,et al.  Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling , 2004, Oncogene.

[34]  P. Atadja,et al.  Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo , 2004, Leukemia.

[35]  J. Downing,et al.  Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Materials and Methods , 2022 .

[36]  G. Webersinke,et al.  p53-Binding Protein 1 Is Fused to the Platelet-Derived Growth Factor Receptor β in a Patient with a t(5;15)(q33;q22) and an Imatinib-Responsive Eosinophilic Myeloproliferative Disorder , 2004, Cancer Research.

[37]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[38]  D. Fabbro,et al.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Ferrando,et al.  Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia , 2004, Nature Genetics.

[40]  K. Ozono,et al.  A novel partner gene CIP29 containing a SAP domain with MLL identified in infantile myelomonocytic leukemia , 2004, Leukemia.

[41]  P. Bühlmann,et al.  Gene Expression Signatures Identify Rhabdomyosarcoma Subtypes and Detect a Novel t(2;2)(q35;p23) Translocation Fusing PAX3 to NCOA1 , 2004, Cancer Research.

[42]  C. Hemenway,et al.  The synthetic peptide PFWT disrupts AF4–AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells , 2004, Leukemia.

[43]  S. Asano,et al.  A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2004, Blood.

[44]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[45]  S. Armstrong,et al.  FLT3 mutations in childhood acute lymphoblastic leukemia. , 2004, Blood.

[46]  Y. Hayashi,et al.  FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. , 2003, Blood.

[47]  S. Armstrong,et al.  FLT3 mutations in childhood acute lymphoblastic leukemia. , 2004, Blood.

[48]  P. Atadja,et al.  Histone deacetylase inhibitor NVP-LAQ 824 has significant activity against myeloid leukemia cells in vitro and in vivo , 2004 .

[49]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[50]  J. Sklar,et al.  TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms , 1991, Cell.